3 Top Nuclear Stocks to Buy Right Now

Uranium prices rose ~34% year-over-year, supporting Cameco (CCJ) which produced ~15% of global uranium and reported revenue of $3.4B (+11% vs 2024) with a 16.9% net margin and 0.14 D/E. BWX Technologies (BWXT) delivered $3.19B revenue (+18% vs 2024) and EPS growth of ~20% with a 10.3% net margin, while advancing SMR technology as a non-core but promising line. Constellation Energy (CEG) posted revenue and adjusted operating EPS growth of ~8% for 2025, a 9.1% net margin, a 0.83% yield, and announced consecutive 10% dividend increases, indicating steady cash returns for shareholders.

Analysis

The current nuclear narrative is moving from commodity-driven price calls to a bifurcated industrial thesis: (A) upstream commodity tightness that can re-rate miners if contracted demand outpaces new supply over 12–36 months, and (B) downstream capex and IP winners among reactor builders and component manufacturers. The key second-order lever is manufacturing cadence — firms that can standardize factory-built modules and secure long lead-time forgings/electronics will convert pilot programs into multi-year backlog with much higher margin visibility than project developers reliant on one-off EPC contracts.

Geopolitics is acting as a macro accelerant but also introduces asymmetric tail risk: trade frictions, sanctions, or shipping disruptions can shrink available secondary uranium or enrichment services quickly, lifting spot prices, yet the same shocks can freeze cross-border reactor supply chains and delay cash flows for builders for 6–24 months. Financing is the underrated constraint — many proposed SMR and new-build projects are economic only with long-term contracts or state-backed capital; absence of secured offtakes turns optionality into binary litigation and delay exposure.

Investor positioning should therefore separate commodity exposure from execution exposure. Own firms with recurring, defense-like cashflows and deep IP in reactor components to capture margin expansion, while keeping uranium exposure via option structures to limit downside if global inventories normalize. Finally, the consensus is underweight timing risk: market euphoria around “renaissance” misses licensing and factory-scale risk that typically compresses realised returns in years 1–3 even when final economics look attractive in years 4–8.

Key Decisions for Investors

• Long BWXT (ticker: BWXT) — build a 2–3% position via stock or 18–30 month LEAP calls (buy Jan-2028 15–20% OTM calls). Rationale: capture industrial/IP upside if SMR prototype wins 1–2 factory orders within 12–24 months. Risk/reward: downside limited to ~30–40% on execution delays; upside 50–120% if modular orders translate to visible multi-year backlog. Use 25% trailing stop on delta-equivalent position.
• Uranium convexity via Cameco (ticker: CCJ) call spread — buy 9–15 month call spread to express a spot-tightening scenario while capping premium. Example structure: buy 12–18 month calls ~ATM and sell higher strike to finance premium. Rationale: preserves upside if secondary supply tightens while limiting drawdown if inventories are released. Risk/reward: capped losses equal to premium (~100% of premium), asymmetrical upside if spot rallies 30%+ within 6–12 months.
• Relative-value pair: long BWXT / short Brookfield (ticker: BAM) — equal notional exposure over 9–18 months to isolate manufacturing/IP execution vs capital-constr. Thesis: BWXT benefits from factory-scale manufacturing and recurring defense/utility contracts; BAM-exposed assets (via large-scale project financing) carry higher event risk from overruns. Risk/reward: if SMR industrialisation accelerates, expect pair to outperform by 30–60%; if commodity shock or broad risk-off, both may fall — size shorts smaller (0.5x) to limit beta mismatch.
• Utility hedge: buy Constellation (ticker: CEG) and purchase 6–12 month 7–10% OTM protective puts (~1–2% cost). Rationale: preserves dividend-like exposure to contracted generation while protecting against near-term wholesale price shocks or regulatory setbacks. Risk/reward: capped downside to put cost plus strike gap; steady mid-single-digit yield-like return if no adverse catalysts.